CN101780037A - 双嘧达莫自乳化给药系统及其制备方法 - Google Patents
双嘧达莫自乳化给药系统及其制备方法 Download PDFInfo
- Publication number
- CN101780037A CN101780037A CN201010105210A CN201010105210A CN101780037A CN 101780037 A CN101780037 A CN 101780037A CN 201010105210 A CN201010105210 A CN 201010105210A CN 201010105210 A CN201010105210 A CN 201010105210A CN 101780037 A CN101780037 A CN 101780037A
- Authority
- CN
- China
- Prior art keywords
- dipyridamole
- self
- emulsifying
- administration system
- medicament administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002768 dipyridamole Drugs 0.000 title claims abstract description 83
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims abstract description 83
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000000839 emulsion Substances 0.000 claims abstract description 18
- 239000002245 particle Substances 0.000 claims abstract description 14
- 238000003756 stirring Methods 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000001727 in vivo Methods 0.000 claims abstract description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 36
- 239000007901 soft capsule Substances 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 19
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 14
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 14
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 14
- 239000005642 Oleic acid Substances 0.000 claims description 14
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 14
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 14
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000004064 cosurfactant Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- -1 polyoxyethylene Polymers 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 230000002269 spontaneous effect Effects 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- 239000007902 hard capsule Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 3
- 230000005176 gastrointestinal motility Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 2
- RNMDNPCBIKJCQP-UHFFFAOYSA-N 5-nonyl-7-oxabicyclo[4.1.0]hepta-1,3,5-trien-2-ol Chemical compound C(CCCCCCCC)C1=C2C(=C(C=C1)O)O2 RNMDNPCBIKJCQP-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920000151 polyglycol Polymers 0.000 claims description 2
- 239000010695 polyglycol Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 6
- 239000002775 capsule Substances 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000008855 peristalsis Effects 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 14
- 239000002671 adjuvant Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000012377 drug delivery Methods 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000006219 Herpangina Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- NPTLAYTZMHJJDP-KTKRTIGZSA-N [3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO NPTLAYTZMHJJDP-KTKRTIGZSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101052109A CN101780037B (zh) | 2010-02-03 | 2010-02-03 | 双嘧达莫自乳化给药系统及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101052109A CN101780037B (zh) | 2010-02-03 | 2010-02-03 | 双嘧达莫自乳化给药系统及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101780037A true CN101780037A (zh) | 2010-07-21 |
CN101780037B CN101780037B (zh) | 2011-11-16 |
Family
ID=42520268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101052109A Expired - Fee Related CN101780037B (zh) | 2010-02-03 | 2010-02-03 | 双嘧达莫自乳化给药系统及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101780037B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102488648A (zh) * | 2011-12-29 | 2012-06-13 | 青岛农业大学 | 氟苯尼考自微乳的配制方法 |
CN106389329A (zh) * | 2016-12-05 | 2017-02-15 | 黑龙江童医生儿童生物制药有限公司 | 一种双嘧达莫口服乳剂给药系统及其制备方法 |
CN107106541A (zh) * | 2015-01-28 | 2017-08-29 | 瑞采生技有限公司 | 用于增强PPARγ表现及核转位之化合物及其医疗用途 |
CN108210454A (zh) * | 2016-12-14 | 2018-06-29 | 深圳市华力康生物医药有限公司 | 一种帕布昔利布的口服乳剂及其制备方法 |
US10736842B2 (en) | 2014-06-25 | 2020-08-11 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
CN112353761A (zh) * | 2020-11-24 | 2021-02-12 | 中国药科大学 | 一种双嘧达莫的自纳米乳制剂及其制备方法 |
US11400048B2 (en) | 2014-06-25 | 2022-08-02 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0317869D0 (en) * | 2003-07-30 | 2003-09-03 | Disperse Ltd | Improved drug delivery system |
CN1586484A (zh) * | 2004-07-12 | 2005-03-02 | 北京瑞伊人科技发展有限公司 | 双嘧达莫软胶囊制剂及其制备方法 |
WO2007092026A1 (en) * | 2006-02-09 | 2007-08-16 | Teva Pharmaceutical Industries Ltd. | Dipyridamole extended-release formulations and process for preparing same |
CN101234094B (zh) * | 2008-03-14 | 2010-09-22 | 北京联合大学生物化学工程学院 | 双嘧达莫口崩片 |
-
2010
- 2010-02-03 CN CN2010101052109A patent/CN101780037B/zh not_active Expired - Fee Related
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102488648A (zh) * | 2011-12-29 | 2012-06-13 | 青岛农业大学 | 氟苯尼考自微乳的配制方法 |
US10736842B2 (en) | 2014-06-25 | 2020-08-11 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
US11400048B2 (en) | 2014-06-25 | 2022-08-02 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
CN107106541A (zh) * | 2015-01-28 | 2017-08-29 | 瑞采生技有限公司 | 用于增强PPARγ表现及核转位之化合物及其医疗用途 |
EP3250201A4 (en) * | 2015-01-28 | 2018-08-01 | Realinn Life Science Limited | Compounds for enhancing ppar expression and nuclear translocation and therapeutic use thereof |
CN115282152A (zh) * | 2015-01-28 | 2022-11-04 | 瑞采生技有限公司 | 用于增强PPARγ表现及核转位之化合物及其医疗用途 |
CN106389329A (zh) * | 2016-12-05 | 2017-02-15 | 黑龙江童医生儿童生物制药有限公司 | 一种双嘧达莫口服乳剂给药系统及其制备方法 |
CN106389329B (zh) * | 2016-12-05 | 2019-03-19 | 黑龙江童医生儿童生物制药有限公司 | 一种双嘧达莫口服乳剂给药系统及其制备方法 |
CN108210454A (zh) * | 2016-12-14 | 2018-06-29 | 深圳市华力康生物医药有限公司 | 一种帕布昔利布的口服乳剂及其制备方法 |
CN112353761A (zh) * | 2020-11-24 | 2021-02-12 | 中国药科大学 | 一种双嘧达莫的自纳米乳制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101780037B (zh) | 2011-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101780037B (zh) | 双嘧达莫自乳化给药系统及其制备方法 | |
CN101862306B (zh) | 新型难溶性药物口服固体自乳化制剂及其制备方法 | |
CN100463670C (zh) | 用于不溶于水的抗感冒药物口服给药的微乳浓缩液及其制备方法 | |
JP5491724B2 (ja) | 生物学的利用能を向上した医薬組成物 | |
CN102949375B (zh) | 一种盐酸小檗碱固体脂质纳米制剂及其制备方法 | |
CN101926757A (zh) | 一种难溶性药物的液体组合物及其制备方法 | |
CN101390851B (zh) | 双环醇含表面活性剂的药物组合物及其制备方法和制剂 | |
CN103249403A (zh) | 胡桐素及胡桐素衍生物和类似物的药物组合物及其制备方法 | |
CN101601695B (zh) | 灵芝三萜提取物的自微乳化纳米组合物及其制备方法 | |
CN100536921C (zh) | 过饱和阳离子自乳化给药系统及其制备方法 | |
CN100518831C (zh) | 固体纳米药物及其制备方法 | |
CN102784096B (zh) | 一种积雪草酸自微乳化给药系统及其制备方法 | |
CN102274188A (zh) | 一种含穿心莲内酯的固体脂质纳米粒及其制备方法和应用 | |
CN103690482B (zh) | 以磷脂复合物为中间体的甘草酸自乳化制剂用浓缩液及制备方法 | |
CN103282022A (zh) | 包含阿拉泊韦的药物组合物 | |
CN102319302B (zh) | 赤芍总苷自微乳化软胶囊及其制备方法 | |
CN108498455B (zh) | 一种油性水溶药物纳米晶及其制备方法 | |
CN102058577B (zh) | 一种以双环醇为活性成分的药物组合物及其制剂 | |
CN105769810A (zh) | 一种恩替卡韦自微乳化制剂 | |
CN101492489A (zh) | 银莲花素a的提取方法及其脂微球制剂的制备方法 | |
CN102274274B (zh) | 可自微乳化的葛根黄酮口服微丸组合物及其制备方法 | |
WO2020210723A1 (en) | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability | |
CN100525775C (zh) | 葛根黄酮自微乳化软胶囊及其制备方法 | |
CN100515427C (zh) | 灯盏花素自乳化软胶囊及其制备方法 | |
CN101618015A (zh) | 水飞蓟宾复合物微乳组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shenzhen Hepalink Pharmaceutical Co., Ltd. Assignor: Nanchang University Contract record no.: 2011990001118 Denomination of invention: Dipyridamole self-emulsifying medicament administration system and preparation method thereof Granted publication date: 20111116 License type: Exclusive License Open date: 20100721 Record date: 20111226 |
|
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN HEPALINK PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NANCHANG UNIVERSITY Effective date: 20120302 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 330000 NANCHANG, JIANGXI PROVINCE TO: 518057 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120302 Address after: 518057 Guangdong city of Shenzhen province Nanshan District Pine Hill Lang Road No. 21 Patentee after: Shenzhen Hepalink Pharmaceutical Co., Ltd. Address before: 999 No. 330000 Jiangxi province Nanchang Honggutan University Avenue Patentee before: Nanchang University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111116 Termination date: 20160203 |
|
CF01 | Termination of patent right due to non-payment of annual fee |